Observational analysis found similar overall survival and relapse incidence in patients post-transplant, suggesting 80 mg/kg cyclophosphamide may reduce toxicities.
Key Points
PTCy dosing of 80 mg/kg showed comparable overall survival with no significant differences in relapse rates.
One-year overall survival was 92.6% for PTCy80 and 88.9% for PTCy100, indicating both doses are effective.
Retrospective chart review assessed outcomes like toxicity, GVHD incidence, and hospital length of stay among patients.
Indicates that reduced PTCy dosing may provide a viable option for patients at risk for toxicity.